Approval · Notice of Compliance 16342 · 2014
LETROZOLE: Notice of Compliance 16342
Issued November 21, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16342
- Date
- November 21, 2014
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Non-steroidal aromatase inhibitor; inhibitor of estrogen biosynthesis; anti-tumour agent
- Canadian reference product
- FEMARA (Novartis Pharmaceuticals Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LETROZOLE | 02348969 | Cancelled Post Market |
Medicinal ingredients
- LETROZOLE 2.5 MG per TAB